Business Description
Sequana Medical NV
ISIN : BE0974340722
Total Employee Number:
48Description
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.18 | |||||
Equity-to-Asset | -2.69 | |||||
Debt-to-Equity | -1.06 | |||||
Debt-to-EBITDA | -1.04 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -54.25 | |||||
Beneish M-Score | -11.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -46.9 | |||||
3-Year EBITDA Growth Rate | 2.9 | |||||
3-Year EPS without NRI Growth Rate | 2.1 | |||||
3-Year FCF Growth Rate | 25 | |||||
3-Year Book Growth Rate | -187.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 39.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 469.22 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.02 | |||||
9-Day RSI | 57.84 | |||||
14-Day RSI | 55.78 | |||||
3-1 Month Momentum % | 15.84 | |||||
6-1 Month Momentum % | -11.72 | |||||
12-1 Month Momentum % | -61.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.2 | |||||
Quick Ratio | 0.16 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 29348.7 | |||||
Days Sales Outstanding | 148.07 | |||||
Days Payable | 31268.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.7 | |||||
Shareholder Yield % | -49.87 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.53 | |||||
Operating Margin % | -17191.51 | |||||
Net Margin % | -42126.42 | |||||
EBITDA Margin % | -38794.34 | |||||
FCF Margin % | -16690.57 | |||||
OCF Margin % | -16628.3 | |||||
ROA % | -440.62 | |||||
ROIC % | -41.4 | |||||
3-Year ROIIC % | 9.09 | |||||
ROC (Joel Greenblatt) % | -2168.62 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 203.67 | |||||
EV-to-EBIT | -2.01 | |||||
EV-to-EBITDA | -2.06 | |||||
EV-to-Revenue | 772.18 | |||||
EV-to-Forward-Revenue | 161.6 | |||||
EV-to-FCF | -4.63 | |||||
Price-to-GF-Value | 2.69 | |||||
Earnings Yield (Greenblatt) % | -49.75 | |||||
FCF Yield % | -37.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sequana Medical NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.106 | ||
| EPS (TTM) (€) | -1.23 | ||
| Beta | 0.6862 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.47 | ||
| Volatility % | 70.02 | ||
| 14-Day RSI | 55.78 | ||
| 14-Day ATR (€) | 0.001571 | ||
| 20-Day SMA (€) | 0.512 | ||
| 12-1 Month Momentum % | -61.56 | ||
| 52-Week Range (€) | 0.3695 - 1.474 | ||
| Shares Outstanding (Mil) | 78.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sequana Medical NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sequana Medical NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-24 | In 81 days | ||
| General meeting for 2025 | 2026-05-28 09:00 | 0.51 (+0.00%) | ||
| General meeting for 2025 | 2026-05-22 09:00 | 0.51 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-12 07:00 | 0.51 (+0.00%) | ||
| Annual report for 2025 | 2026-04-28 | 0.46 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-24 | 0.98 (+9.39%) | ||
| General meeting for 2024 | 2025-05-22 09:00 | 0.94 (+0.00%) | ||
| Annual report for 2024 | 2025-04-21 | 1.01 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-17 07:00 | 1.46 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-19 | 0.95 (+0.00%) |
Show
Entries
Sequana Medical NV Frequently Asked Questions
What is Sequana Medical NV(FRA:2SE)'s stock price today?
The current price of FRA:2SE is €0.51. The 52 week high of FRA:2SE is €1.47 and 52 week low is €0.37.
When is next earnings date of Sequana Medical NV(FRA:2SE)?
The next earnings date of Sequana Medical NV(FRA:2SE) is 2026-09-24 Est..
Does Sequana Medical NV(FRA:2SE) pay dividends? If so, how much?
Sequana Medical NV(FRA:2SE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sequana Medical NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers